Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.
about
Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory AnalysisHeritable GATA2 mutations associated with familial AML-MDS: a case report and review of literatureFLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.The Future of Targeting FLT3 Activation in AML.Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseArsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.Δ-PCR, A Simple Method to Detect Translocations and Insertion/Deletion Mutations.Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence dataFLT3: ITDoes matter in leukemia.Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.Internal tandem duplications of the FLT3 gene are present in leukemia stem cellsClinical implications of FLT3 mutations in pediatric AML.Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length.A molecular fraction collecting tool for the ABI 310 automated sequencer.Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML.Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsCytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients.Tandem duplication PCR: an ultrasensitive assay for the detection of internal tandem duplications of the FLT3 gene.Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.How I treat FLT3-mutated AML.FLT3 inhibitors in acute myeloid leukemia.Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.Delayed processing of bone marrow samples reveals a prognostic pattern of NME mRNA expression in cytogenetically normal acute myeloid leukemia.Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.FLT3-ITD and its current role in acute myeloid leukaemia.Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.A robust xenotransplantation model for acute myeloid leukemia.Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study.
P2860
Q26797245-2EADAA84-5E6D-4A46-A837-14B501A1B66EQ26828941-4AEC2102-E998-4E68-8334-BC9202D42016Q27028163-88FED821-DC1F-408F-A11C-274573AAAE37Q33421005-8D233050-8085-4A4E-9739-C902A7DAD37CQ33437313-538A5713-CAE3-49F4-BA05-36A9B62880AFQ33555627-D9BEF7E2-8348-4635-8E82-92E7634BBE66Q33680292-2B5C9601-B839-4327-B903-1B2F03E0C504Q34011740-D7C12DC3-5D2B-4B19-8A4E-CF3A2EB520CEQ34555386-70C7A7E0-8BC4-4F6D-9A59-DB3E9C13DF0BQ34620761-8E65680E-A8F6-40D0-8A22-24598CDD9783Q34754344-56394F98-3FE6-4600-B072-CCCD43C378DBQ34754867-9F30157D-BDD8-4255-A859-2DF55E6900BBQ34756095-32C35591-C57B-4EE1-AE2E-3CDCE13CDBBFQ35037810-45270E12-6EFF-4587-A505-5FDE503BCD40Q35217399-DF01708F-D0A7-4E06-B513-72D2682D9BADQ35688721-220A4310-D95D-4942-BB2D-41211CC95B8DQ35800831-887ED9E0-3E10-46EC-AF9C-B77C7ED2524BQ35847990-84A61D2B-3961-4A35-A834-CB97B5B5E8D0Q35848876-FD0115A0-0B27-4BE3-A5DD-11AF88ABEA30Q36022521-6FD82C54-1568-493E-9AB9-FDE41099FEDEQ36103442-B07B9524-E9C2-4EB9-9F61-D718432C7527Q36153422-B6F8B9AA-5040-4565-A27B-6613025474B0Q36304815-68F14E29-CA5C-49A1-912B-2A02A2E16441Q36469916-876CA09B-13BD-4491-8E82-69044D9B22DDQ36734284-D379698A-7788-4FDA-AA70-D1D19437DFCFQ37097761-41E1FE07-F1C8-4B14-8D68-652D1609B8E0Q37133515-0962514B-2EE6-4A07-8582-C931848D9AF8Q37373040-4E0381CC-21E9-4068-A3B5-2AC6FC3EDE7BQ37377901-4A610D39-18D0-4717-9378-164C7464C1DEQ37623389-719C5536-A89C-4CC0-A704-72718BD0F4D0Q37810061-B8EC3F00-46A3-4F13-ADF5-8D1F1A7E8D3FQ37842861-236E0652-124F-434B-BA4C-32D3257E20B9Q38062865-4A246A7B-BC30-4F55-A143-BA323A79437BQ38404740-D5E9922E-4171-4044-97CE-CB27BAA5F521Q39135512-888D9797-C2BF-4BDE-BE4B-79866B19344BQ39282600-3FB8BA35-160D-4683-85CE-D141BE4F48F5Q40325678-C57A30ED-729C-45A0-9AC0-58D32AECFC8EQ40396505-F30F902D-C757-4D08-B9C6-1DF52E19DD09Q40886338-A1B24733-19BF-47C9-AB99-AE68A4E2BBAAQ41051992-BED17C92-FD4B-4C65-99EA-0DDFF75DDD53
P2860
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Detection of FLT3 internal tan ...... pillary electrophoresis assay.
@en
Detection of FLT3 internal tan ...... pillary electrophoresis assay.
@nl
type
label
Detection of FLT3 internal tan ...... pillary electrophoresis assay.
@en
Detection of FLT3 internal tan ...... pillary electrophoresis assay.
@nl
prefLabel
Detection of FLT3 internal tan ...... pillary electrophoresis assay.
@en
Detection of FLT3 internal tan ...... pillary electrophoresis assay.
@nl
P2093
P2860
P1476
Detection of FLT3 internal tan ...... pillary electrophoresis assay.
@en
P2093
B Douglas Smith
Donald Small
Karin D Berg
Kathleen M Murphy
Lisa C Cooper
Mark Levis
Michael J Hafez
Tanya Geiger
P2860
P304
P356
10.1016/S1525-1578(10)60458-8
P577
2003-05-01T00:00:00Z